MX2020008704A - Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. - Google Patents
Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro.Info
- Publication number
- MX2020008704A MX2020008704A MX2020008704A MX2020008704A MX2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A MX 2020008704 A MX2020008704 A MX 2020008704A
- Authority
- MX
- Mexico
- Prior art keywords
- bupropion
- dosage forms
- enantiomerically enriched
- methods
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634718P | 2018-02-23 | 2018-02-23 | |
| US201962794469P | 2019-01-18 | 2019-01-18 | |
| US201962809480P | 2019-02-22 | 2019-02-22 | |
| PCT/US2019/019445 WO2019165379A1 (en) | 2018-02-23 | 2019-02-25 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020008704A true MX2020008704A (es) | 2020-12-07 |
Family
ID=67688503
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020008704A MX2020008704A (es) | 2018-02-23 | 2019-02-25 | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro. |
| MX2023009281A MX2023009281A (es) | 2018-02-23 | 2020-08-20 | Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009281A MX2023009281A (es) | 2018-02-23 | 2020-08-20 | Formas y metodos de dosis para bupropion enantiomericamente enriquecido o puro. |
Country Status (19)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3092076A1 (en) * | 2018-02-23 | 2019-08-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| CN114423417A (zh) * | 2019-09-20 | 2022-04-29 | 艾克萨姆治疗公司 | 用于对映体富集的或纯的安非他酮的剂型和方法 |
| US20250073188A1 (en) | 2020-06-05 | 2025-03-06 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
| US11717518B1 (en) | 2022-06-30 | 2023-08-08 | Antecip Bioventures Ii Llc | Bupropion dosage forms with reduced food and alcohol dosing effects |
| US12036191B1 (en) | 2022-06-30 | 2024-07-16 | Antecip Bioventures Ii Llc | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
| US12156914B2 (en) | 2022-06-30 | 2024-12-03 | Axsome Therapeutics, Inc. | Pharmaceutical compositions comprising bupropion and cysteine |
| US11730706B1 (en) | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| KR20250114110A (ko) | 2022-11-28 | 2025-07-28 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 약물 활성의 조절제로서의 부프로피온 |
| WO2025259728A1 (en) * | 2024-06-13 | 2025-12-18 | Antecip Bioventures Ii Llc | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999038502A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6337328B1 (en) * | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| CN1819821B (zh) * | 2003-08-08 | 2010-10-13 | 拜奥维尔实验室国际股份有限公司 | 盐酸安非他酮的改良释放片剂 |
| WO2012118562A1 (en) * | 2011-03-02 | 2012-09-07 | Rhine Pharmaceuticals, Llc | Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations |
| EP3981403A1 (en) * | 2013-11-05 | 2022-04-13 | Antecip Bioventures II LLC | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
| US9474731B1 (en) * | 2013-11-05 | 2016-10-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| US10080727B2 (en) * | 2013-11-05 | 2018-09-25 | Antecip Bioventures Ii Llc | Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects |
| MX2013014166A (es) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Enantiomeros activos y sus sales para el tratamiento de la obesidad. |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| CA3092076A1 (en) * | 2018-02-23 | 2019-08-29 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2019
- 2019-02-25 CA CA3092076A patent/CA3092076A1/en active Pending
- 2019-02-25 CN CN201980026874.5A patent/CN112087999A/zh active Pending
- 2019-02-25 MX MX2020008704A patent/MX2020008704A/es unknown
- 2019-02-25 NZ NZ767378A patent/NZ767378A/en unknown
- 2019-02-25 MA MA051914A patent/MA51914A/fr unknown
- 2019-02-25 SG SG11202008056SA patent/SG11202008056SA/en unknown
- 2019-02-25 AU AU2019223187A patent/AU2019223187B2/en active Active
- 2019-02-25 IL IL276871A patent/IL276871B2/en unknown
- 2019-02-25 KR KR1020247017593A patent/KR20240091043A/ko not_active Ceased
- 2019-02-25 WO PCT/US2019/019445 patent/WO2019165379A1/en not_active Ceased
- 2019-02-25 CR CR20200415A patent/CR20200415A/es unknown
- 2019-02-25 JP JP2020544420A patent/JP2021513998A/ja active Pending
- 2019-02-25 KR KR1020207027256A patent/KR20210003091A/ko not_active Ceased
- 2019-02-25 BR BR112020017179-4A patent/BR112020017179A2/pt not_active Application Discontinuation
- 2019-02-25 CN CN202510967625.3A patent/CN120827545A/zh active Pending
- 2019-02-25 KR KR1020237017449A patent/KR20230075531A/ko not_active Ceased
- 2019-02-25 MY MYPI2020004315A patent/MY202993A/en unknown
- 2019-02-25 EP EP19756920.5A patent/EP3755312A4/en active Pending
- 2019-02-25 IL IL313368A patent/IL313368A/en unknown
- 2019-02-25 PE PE2020001272A patent/PE20211752A1/es unknown
-
2020
- 2020-08-20 MX MX2023009281A patent/MX2023009281A/es unknown
- 2020-08-21 NI NI202000056A patent/NI202000056A/es unknown
- 2020-08-21 CL CL2020002166A patent/CL2020002166A1/es unknown
- 2020-09-23 EC ECSENADI202060179A patent/ECSP20060179A/es unknown
-
2022
- 2022-06-27 AU AU2022204521A patent/AU2022204521B2/en active Active
- 2022-08-04 JP JP2022124557A patent/JP2022153638A/ja active Pending
-
2024
- 2024-03-15 JP JP2024041381A patent/JP2024075655A/ja active Pending
- 2024-08-17 AU AU2024205858A patent/AU2024205858A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3092076A1 (en) | 2019-08-29 |
| PE20211752A1 (es) | 2021-09-06 |
| CN120827545A (zh) | 2025-10-24 |
| AU2019223187A1 (en) | 2020-09-17 |
| NI202000056A (es) | 2021-01-11 |
| IL276871A (en) | 2020-10-29 |
| JP2021513998A (ja) | 2021-06-03 |
| MY202993A (en) | 2024-05-31 |
| KR20240091043A (ko) | 2024-06-21 |
| IL276871B2 (en) | 2024-11-01 |
| AU2024205858A1 (en) | 2024-09-05 |
| IL313368A (en) | 2024-08-01 |
| WO2019165379A1 (en) | 2019-08-29 |
| ECSP20060179A (es) | 2020-12-31 |
| CN112087999A (zh) | 2020-12-15 |
| MX2023009281A (es) | 2023-08-17 |
| EP3755312A1 (en) | 2020-12-30 |
| BR112020017179A2 (pt) | 2020-12-22 |
| KR20230075531A (ko) | 2023-05-31 |
| AU2022204521A1 (en) | 2022-07-21 |
| CL2020002166A1 (es) | 2020-10-23 |
| AU2022204521B2 (en) | 2024-09-05 |
| NZ767378A (en) | 2024-03-22 |
| JP2024075655A (ja) | 2024-06-04 |
| AU2019223187B2 (en) | 2022-07-28 |
| CR20200415A (es) | 2021-02-03 |
| MA51914A (fr) | 2020-12-30 |
| SG11202008056SA (en) | 2020-09-29 |
| IL276871B1 (en) | 2024-07-01 |
| KR20210003091A (ko) | 2021-01-11 |
| EP3755312A4 (en) | 2022-03-16 |
| JP2022153638A (ja) | 2022-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI202000056A (es) | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro | |
| ES3063891T3 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| CL2021003306A1 (es) | Agentes, usos y métodos para el tratamiento de la sinucleinopatía. (divisional de solicitud nº 201901293) | |
| MX2020012966A (es) | Combinacion, composicion y preparacion de combinacion farmaceutica que comprende activador de glucocinasa e inhibidor de sglt-2, metodos de preparacion y usos de las mismas. | |
| SV2018005612A (es) | Agentes, usos y metodos para el tratamiento de la sinucleinopatia | |
| MX2016010235A (es) | Composicion farmaceutica que comprende eritrocitos que encapsulan una enzima dependiente de fosfato de piridoxal (plp) y su cofactor. | |
| GT201600137A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
| CL2022001178A1 (es) | Ligandos de la pseudoquinasa tyk2 | |
| CL2016002560A1 (es) | Forma de dosificación farmacéutica sólida oral que comprende siponimod, un agente protector de la humedad y opcionalmente un excipiente farmacéutico; procedimiento de preparación. | |
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| AR116451A1 (es) | Administración oral de análogos del péptido glp-1 | |
| MX2021008432A (es) | Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal. | |
| CL2020003143A1 (es) | Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria | |
| BR112018074655A2 (pt) | formulação injetável de fosnetupitant e método de fabricação de uma formulação | |
| MX2016014740A (es) | Un metodo para el tratamiento de trastornos del movimiento con befiradol. | |
| BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
| ECSP22030119A (es) | Formas de dosificación y métodos para bupropión enantioméricamente enriquecido o puro | |
| MX381450B (es) | Un medicamento combinado que comprende fenilefrina y paracetamol | |
| EP4631500A3 (en) | STABLE MULTIPARTICULAR PHARMACEUTICAL COMPOSITION OF ROSUVASTATIN | |
| MX2018010367A (es) | Titulacion de cebranopadol. | |
| MY203254A (en) | Pharmaceutical preparation | |
| MX2020004403A (es) | Composiciones farmaceuticas que comprenden safinamida. | |
| CO2017000354A2 (es) | Desmopresina estabilizada | |
| BR112021011755A8 (pt) | Método para fornecer um benefício de tratamento bucal com o uso de um composto de cálcio de baixa solubilidade e fluoreto |